Identification of Gene Expression Signature in Estrogen Receptor Positive Breast Carcinoma

A significant group of patient with estrogen receptor (ER) α positive breast tumors fails to appreciably respond to endocrine therapy. An increased understanding of the molecular basis of estrogen-mediated signal transduction and resultant gene expression may lead to novel strategies for treating breast cancer. In this study, we sought to identify the dysregulated genes in breast tumors related to ERα status. Microarray analyses of 31 tumor samples showed 108 genes differentially expressed in ERα (+) and ERα (–) primary breast tumors. Further analyses of gene lists indicated that a significant number of dysregulated genes were involved in mRNA transcription and cellular differentiation. The majority of these genes were found to have promoter-binding sites for E74-like factor 5 (ELF5; 54.6% genes), E2F transcription factor 1 (E2F1; 22.2% genes), and nuclear transcription factor Y alpha (NFYA; 32.4% genes). Six candidate genes (NTN4, SLC7A8, MLPH, ENPP1, LAMB2, and PLAT) with differential expression were selected for further validation studies using RT-qPCR (76 clinical specimen) and immunohistochemistry (48 clinical specimen). Our studies indicate significant overexpression of all the six genes in ERα (+) breast tumors as compared to ERα (–) breast tumors. In vitro studies using T-47D breast cancer cell line confirmed the estrogen dependant expression of four of the above six genes (SLC7A8, ENPP1, LAMB2, and PLAT). Collectively, our study provides further insights into the molecular basis of estrogen-dependent breast cancer and identifies “candidate biomarkers” that could be useful for predicting endocrine responsiveness.

[1]  G. Thomas,et al.  A new member of the ETS family fused to EWS in Ewing tumors , 1997, Oncogene.

[2]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[3]  Q. Ye,et al.  Ligand‐independent activation of estrogen receptor α by XBP‐1 , 2003 .

[4]  G. Thomas,et al.  Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors. , 1997, Cancer genetics and cytogenetics.

[5]  K. Tryggvason,et al.  Laminin isoforms in tumor invasion, angiogenesis and metastasis. , 2002, Seminars in cancer biology.

[6]  Barry Komm,et al.  Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. , 2007, Molecular endocrinology.

[7]  Steve Horvath,et al.  Breast Cancer Molecular Signatures as Determined by SAGE: Correlation with Lymph Node Status , 2007, Molecular Cancer Research.

[8]  Q. Ye,et al.  Ligand-independent activation of estrogen receptor alpha by XBP-1. , 2003, Nucleic Acids Research.

[9]  R. Buckle,et al.  Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. , 1998, Genes & development.

[10]  Michael J Thun,et al.  Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women , 2007, Breast Cancer Research.

[11]  Lars S Jermiin,et al.  A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines , 1998, Oncogene.

[12]  Hugues Bersini,et al.  Integration and cross‐validation of high‐throughput gene expression data: comparing heterogeneous data sets , 2003, FEBS letters.

[13]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[14]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  John H. White,et al.  Genome-wide identification of high-affinity estrogen response elements in human and mouse. , 2004, Molecular endocrinology.

[16]  Jorge S Reis-Filho,et al.  Identification of NTN4, TRA1, and STC2 as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins , 2007, Clinical Cancer Research.

[17]  L. Chung,et al.  PC-1/PrLZ contributes to malignant progression in prostate cancer. , 2007, Cancer research.

[18]  K. Korach,et al.  The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[19]  S. Vacher,et al.  Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.

[20]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[21]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[23]  K. Jirström,et al.  High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients , 2006, Clinical Cancer Research.

[24]  D. Belin,et al.  The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.

[25]  E. Simpson.  Sources of estrogen and their importance , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Weigel,et al.  GATA‐3 is expressed in association with estrogen receptor in breast cancer , 1999, International journal of cancer.

[28]  D. McDonnell,et al.  Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. , 2005, Molecular interventions.

[29]  Melissa C Southey,et al.  Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. , 2002, Cancer research.

[30]  Margaret Warner,et al.  Estrogen receptors: how do they signal and what are their targets. , 2007, Physiological reviews.

[31]  P. Nelson,et al.  PrLZ, a Novel Prostate-Specific and Androgen-Responsive Gene of the TPD52 Family, Amplified in Chromosome 8q21.1 and Overexpressed in Human Prostate Cancer , 2004, Cancer Research.

[32]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Korach,et al.  Estrogen receptor null mice: what have we learned and where will they lead us? , 1999, Endocrine reviews.

[34]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[35]  D. Ross,et al.  Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Sharrocks,et al.  The ETS-domain transcription factor family. , 1997, Nature reviews. Molecular cell biology.

[37]  M. Poupon,et al.  Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B , 2008, Proceedings of the National Academy of Sciences.

[38]  P. Chambon,et al.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. , 1982, Nucleic acids research.

[39]  I. Gow,et al.  L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter. , 2004, Biochimica et biophysica acta.

[40]  David J. Arenillas,et al.  oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes , 2005, Nucleic acids research.

[41]  A. Sharrocks.  The ETS-domain transcription factor family , 2001, Nature Reviews Molecular Cell Biology.

[42]  M. Yliperttula,et al.  Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[43]  Kenneth P. Karey,et al.  Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. , 1988, Cancer research.

[44]  M. Shekhar,et al.  Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. , 2001, Cancer research.

[45]  Martin C Frith,et al.  Genomic targets of nuclear estrogen receptors. , 2004, Molecular endocrinology.

[46]  E. Chang,et al.  Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype , 2007, Breast Cancer Research.

[47]  Martín C Abba,et al.  Gene expression signature of estrogen receptor α status in breast cancer , 2005, BMC Genomics.

[48]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[49]  K. Mikoshiba,et al.  Slac2-a/Melanophilin, the Missing Link between Rab27 and Myosin Va , 2002, The Journal of Biological Chemistry.